BioMarin, Invitae, Stoke Therapeutics, and Xenon Pharmaceuticals recently announced the expansion of Behind the Seizures. Previously available to patients ages 2-4 years, the program has expanded to offers Invitae’s comprehensive epilepsy panel at no cost to any child up to 60 months who has had an unprovoked seizure.
More than 50% of epilepsies have some genetic basis, many of which are actionable. Genetic epilepsies may hide behind non-specific symptoms and a delay in diagnosis can be devastating for patients with genetic epilepsy.
Read more about the Behind the Seizures program here.